Eyebiotech Ltd.

This early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…

This study tests a new medication called EYE103 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 1054 adults will receive either EYE103 or a standard treatment (ranibizumab) as eye injections every 4 weeks for the first year, then…